drugset / Trial / NCT05019742
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
Timeline
- Start
- 2022-03-21
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sitokiren | Small molecule | 50 mg | Oral |
| Subject | sitokiren | Small molecule | 100 mg | Oral |